News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
705,732 Results
Type
Article (41836)
Company Profile (473)
Press Release (663423)
Section
Business (208521)
Career Advice (2013)
Deals (35977)
Drug Delivery (97)
Drug Development (83424)
Employer Resources (169)
FDA (16360)
Job Trends (15056)
News (352344)
Policy (33003)
Tag
Academia (2619)
Alliances (50792)
Alzheimer's disease (1338)
Approvals (16313)
Artificial intelligence (176)
Bankruptcy (363)
Best Places to Work (11808)
Biotechnology (355)
Breast cancer (209)
Cancer (1575)
Cardiovascular disease (130)
Career advice (1678)
CAR-T (111)
Cell therapy (334)
Clinical research (66729)
Collaboration (608)
Compensation (312)
COVID-19 (2609)
C-suite (140)
Data (1498)
Diabetes (194)
Diagnostics (6260)
Earnings (86279)
Employer resources (147)
Events (113888)
Executive appointments (502)
FDA (17152)
Funding (543)
Gene therapy (235)
GLP-1 (660)
Government (4426)
Healthcare (19070)
Infectious disease (2706)
Inflammatory bowel disease (121)
Interviews (309)
IPO (16674)
Job creations (3696)
Job search strategy (1430)
Layoffs (451)
Legal (7947)
Lung cancer (231)
Manufacturing (222)
Medical device (13382)
Medtech (13387)
Mergers & acquisitions (19555)
Metabolic disorders (523)
Neuroscience (1728)
NextGen: Class of 2025 (6747)
Non-profit (4541)
Northern California (1897)
Obesity (298)
Opinion (205)
Patents (134)
People (58022)
Phase I (20955)
Phase II (29453)
Phase III (21764)
Pipeline (627)
Postmarket research (2599)
Preclinical (8949)
Radiopharmaceuticals (255)
Rare diseases (307)
Real estate (6002)
Regulatory (22244)
Research institute (2410)
Resumes & cover letters (351)
Southern California (1650)
Startups (3752)
United States (17176)
Vaccines (597)
Weight loss (212)
Date
Today (140)
Last 7 days (430)
Last 30 days (2003)
Last 365 days (35911)
2025 (1875)
2024 (36348)
2023 (41030)
2022 (52279)
2021 (56765)
2020 (54933)
2019 (47422)
2018 (35698)
2017 (33030)
2016 (32354)
2015 (38413)
2014 (32189)
2013 (27115)
2012 (29226)
2011 (29863)
2010 (27993)
Location
Africa (732)
Arizona (211)
Asia (38809)
Australia (6453)
California (4373)
Canada (1571)
China (372)
Colorado (199)
Connecticut (216)
Europe (84614)
Florida (612)
Georgia (147)
Illinois (430)
Indiana (245)
Maryland (706)
Massachusetts (3432)
Michigan (185)
Minnesota (323)
New Jersey (1215)
New York (1226)
North Carolina (850)
Northern California (1897)
Ohio (157)
Pennsylvania (1013)
South America (1107)
Southern California (1650)
Texas (638)
Utah (123)
Washington State (443)
705,732 Results for "effector therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that the Company has terminated its employees and will wind down it operations, including seeking potential strategic alternatives for the Company’s development programs.
June 24, 2024
·
2 min read
Business
eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.
May 9, 2024
·
12 min read
Biotech Bay
eFFECTOR Therapeutics to Participate in Upcoming April 2024 Investor Conference
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that the Company will present at the Stifel Virtual Oncology Forum on Tuesday, April 16th at 11:30 am ET.
April 9, 2024
·
1 min read
Business
eFFECTOR Therapeutics to Collaborate with the Dana-Farber Cancer Institute on an Investigator-Sponsored Phase 2 Clinical Trial Evaluating Zotatifin as Combination Treatment in ER+ Endometrial Cancer
eFFECTOR Therapeutics, Inc. today announced a collaboration to conduct an investigator-sponsored trial (IST) evaluating zotatifin in combination with abemaciclib and letrozole in patients with estrogen receptor-positive (ER+) endometrial cancer.
May 20, 2024
·
6 min read
Biotech Bay
eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced that Steve Worland, Ph.D., president, and chief executive officer of eFFECTOR, will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14th at 10:40 am ET.
February 5, 2024
·
2 min read
Business
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today reported financial results for the fourth quarter and year ended December 31, 2023, and provided a corporate update.
March 25, 2024
·
15 min read
Drug Development
eFFECTOR Therapeutics Announces Topline Results of Phase 2 KICKSTART Trial of Tomivosertib Combined with Pembrolizumab in Non-Small Cell Lung Cancer
eFFECTOR Therapeutics, Inc. today announced topline results from the primary analysis of the randomized Phase 2 KICKSTART trial which tested tomivosertib or placebo, each combined with pembrolizumab, as frontline treatment for patients with non-small cell lung cancer (NSCLC) with PD-L1 ≥50%.
April 4, 2024
·
6 min read
Biotech Bay
eFFECTOR Therapeutics to Host Virtual Investor R&D Day on January 24, 2024
eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”) for the treatment of cancer, today announced that it will host a virtual investor R&D Day on Wednesday, January 24, 2024, at 4:30 pm ET.
January 9, 2024
·
5 min read
Biotech Bay
eFFECTOR Therapeutics to Participate in Fireside Chat at 2023 Stifel Healthcare Conference
eFFECTOR Therapeutics, Inc. today announced that the Company will participate in a fireside chat discussion and host 1x1 meetings at the 2023 Stifel Healthcare Conference taking place November 14-15, 2023 in New York, NY.
November 6, 2023
·
2 min read
Biotech Bay
eFFECTOR Therapeutics Announces Reverse Stock SplitEFTR common stock expected to begin trading on a split-adjusted basis on January 12, 2024
eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, announced that its Board of Directors has approved a 1-for-25 reverse stock split of the Company’s common stock.
January 9, 2024
·
5 min read
1 of 70,574
Next
